ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
https://doi.org/10.20996/1819-6446-2014-10-3-328-333
Abstract
Characteristics of atrial fibrillation pathogenesis in patients with chronic obstructive pulmonary disease are discussed. The impact of chronic obstructive pulmonary disease treatment on the onset and course of atrial fibrillation, as well as approaches to the treatment of atrial fibrillation in this category of patients are also considered.
About the Authors
E. I. Leonova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
G. G. Shehan
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
V. S. Zadionchenko
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
K. M. Bogatyrova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473 Russia
References
1. Chazov E.I., Golitsyn S.P. Guide to heart rhythm irregularities.Moscow: GEOTAR-Media; 2010. (Чазов Е.И., Голицын С.П. Руководство по нарушениям ритма сердца. М.: ГЭОТАР- Медиа; 2010).
2. Camm AJ. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14(10): 1385-413.
3. Guize L, Thomas F, Bean K, et al. Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up. Bull Acad Natl Med 2007;191(4): 791-803.
4. Benjamin EJ, Levy D, Vaziri SM. Independent risk factors for atrial fibrillation in a population-based cohort. The framingham heart study. JAMA 1994;271: 840-4.
5. Stewart S., Hart C.L., Hole D.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew.Paisley Study. Heart 2001;86: 516-21.
6. Buch P. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Resp J 2003;21: 1012-6.
7. Shibata Y, Watanabe T, Osaka D et al. Impairment of Pulmonary Function is an Independent Risk Factor for Atrial Fibrillation: The Takahata Study. Int J Med Sci 2011;8(7): 514-22.
8. Tükek T. Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease. Int J Cardiol 2003;88: 199.
9. Avlova O.V. hormones of adrenal cortex in the blood of patients with chronic obstructive pulmonary disease. Health of Chuvashia 2012; (4): 12-5. Russian (Авлова О.В. Содержание гормонов коры надпочечников в крови у больных хронической обструктивной болезнью легких. Здравоохра-нение Чувашии 2012; (4): 12-5).
10. Tsuji H, Venditti FJ, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. the Framingham Heart Study. Circulation 1994;90: 878-83.
11. Volterrani M. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest 1994;106: 1432-7.
12. Maclay J.D., Mc Alister DA, William M.N. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology 2007;12 (5): 634-41.
13. Ivanov SG, Sitnikova MY, Shlyakhto EV. the Role of oxidative stress in the development and progression of chronic heart failure: the relevance and possibility of its correction. Cardiology CIS 2006; 4: 267-70. Russian (Иванов С.Г., Ситникова М.Ю., Шляхто Е.В. Роль оксидативного стресса в развитии и прогрессировании хронической сердечной недостаточности: актуальность и возможность его коррекции. Кардиология СНГ 2006; 4: 267-70) .
14. Chen L, Einbinder E, Zhang Q, et al. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 2005;172: 915-20.
15. Dumas de La Roque E, Savineau JP, Metivier AC, et al. DHEA enhances lung function in COPD. Ann Endocrinol (Paris) 2012;1: 20-5.
16. Laghi F., Adiguzel N., Tobin M.J. Endocrinological derangements in COPD. Eur Resp J 2009; 34( 4): 975-96.
17. Melnichenko O.V., Nekrasov A.A., Kuznetsov A.N. Factors Associated with the Development of Atrial Fibrillation in Chronic Obstructive Pulmonary Disease. IJBM 2011; 1(2): 71-3.
18. Chen M.C., Chang J.P., Liu W.H. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol 2008;102(7): 861-5.
19. Shujaat A, Minkin R, Eden E. Pulmonary hypertension and chronic cor pulmonale in COPD. J Chron Obstruct Pulmon Dis 2007; 2(3): 273-82.
20. Kang H, Bae BS, Kim JH et al. The relationship between chronic atrial fibrillation and reduced pulmonary function in cases of preserved left ventricular systolic function. Korean Circ J 2009;39: 372-7.
21. Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339: 659-66.
22. Paraskevaidis I.A. Prediction of Successful Cardioversion and Maintenance of Sinus Rhythm in Patients With Lone Atrial Fibrillation. CHEST 2005; 127: 488-94.
23. Heeringa J., van der Kuip D. A., Hofman A. Subclinical atherosclerosis and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2007; 167( 4): 382-7.
24. Caram LM, Ferrari R, Naves CR, et al. Association between left ventricular diastolic dysfunction and severity of chronic obstructive pulmonary disease. Clinics (Sao Paulo) 2013;6: 772-6.
25. Savransky V., Nanayakkara A., Li J. et al. Chronic intermittent hypoxia induces atherosclerosis. American journal of respiratory and critical care medicine 2007;175(12): 1290-7.
26. Feletou M., Vanhoutte P. M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006; 91: 985-1002.
27. Verdejo H. Systemic vascular cell adhesion molecule-1 predicts the occurrence of post-operative atrial fibrillation. Int J Cardiol 2011;150(3): 270-6.
28. Aviles RJ, Martin DO, Apperson-Hansen C. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108: 3006-10.
29. Dong Q., Wright J.R. Expression of C-reactive protein by alveolar macrophages. J Immunol 1996;156: 4815-20.
30. Liuzzo G., Colussi C., Ginnetti F. C-reactive protein directly induces the activation of the transcription factor NFkВ in human monocytes: a clue to pathogenesis of acute coronary syndromes? Eur Heart J 2001; 22: 372.
31. Loricchio M.L., Cianfrocca C., Pasceri V. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007; 99: 1421-4.
32. Alegret JM, Aragonès Gl. The relevance of the association between inflammation and atrial fibrillation. Eur J Clin Invest 2013; 43: 324-31.
33. Yo CH, Lee SH, Chang SS et al. Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis. BMJ 2014;20: 4.
34. Boger R. H. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocysteinemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20: 1557-64.
35. Van Wagoner D. R. Is homocysteine a mediator of atrial dysfunction or just another marker of endothelial dysfunction? Europace 2008; 10( 8): 899-900.
36. Shimano M., Inden Y. Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation. Europace2008;8: 961-6.
37. Wald D. S. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.
38. Global Strategy for Diagnosis, Management, and Prevention of COPD, Updated 2014. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf. Accessed by 15.06.2014.
39. Salpeter SR. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;25(6): 2309-21.
40. Hanrahan J.P., Grogan D.R., Baumgartner R.A., et al. Effect of β-blokers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342: 25-49.
41. Global Strategy for Diagnosis, Management, and Prevention of COPD, 2011. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf. Accessed by 15.06.2014.
42. Moro C, Hernandez-Madrid A, Matia R. Non-antiarrhythmic drugs to prevent atrial fibrillation. Am J Cardiovasc Drugs 2010;10: 165-73.
43. Peña J. M., Macfadyen J., Glynn R.J., Ridker P.M. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012;33: 531-7.
44. Sin D.D., Lacy P., York E., Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170: 760-5.
45. Sin DD. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177: 1207-14.
46. Hothersall E., McSharry C., Thomson N.C. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61: 729-34.
47. Hanrahan J.P., Grogan D.R., Baumgartner R.A. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008;87(6): 319-28.
Review
For citations:
Leonova E.I., Shehan G.G., Zadionchenko V.S., Bogatyrova K.M. ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Rational Pharmacotherapy in Cardiology. 2014;10(3):328-333. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-3-328-333
Views:
1323
Email this article 